34th Annual Report of the Company.
Awaiting price reaction for this filing.
Sarda Proteins Ltd (BSE Scrip: 519242) filed its 34th Annual Report for FY 2024-25 with BSE on September 8, 2025. Revenue from operations surged dramatically to Rs. 2,419.10 lakhs from just Rs. 129.58 lakhs in FY 2023-24, an 18x jump, while net profit after tax declined to Rs. 0.51 lakhs (from Rs. 1.94 lakhs previously), indicating extremely thin margins of around 0.02%. The Board did not declare any dividend citing insufficient profits, and the share capital structure remained unchanged with paid-up capital of Rs. 2.50 crores. The 34th Annual General Meeting is scheduled for Tuesday, September 30, 2025 at 2:00 PM via video conferencing, where shareholders will vote on adopting financial statements, re-appointing Managing Director Mr. Chirag Shantilal Thumar, appointing new statutory auditor M/s. S. D. Mehta & Co. for 6 years, and appointing M/s. H. Togadiya & Associates as secretarial auditor for 5 years (FY 2025-26 to FY 2029-30). The e-voting cut-off date is September 23, 2025.
The massive revenue growth is a positive sign of business expansion, but the negligible net profit and absence of dividend may concern income-focused investors. The items on the AGM agenda are largely routine compliance matters, with no major strategic announcements likely to move the stock price.